ClinicalTrials.gg

Program

Base Edited Natural Killer Cells NK510

Also written as “NK510” and “NK510 : allogeneic genetic modified NK”.

Its studies are mostly in Stomach Neoplasms · Lupus Erythematosus, Systemic · Osteosarcoma, led by Base Therapeutics (Shanghai).

Furthest: early phase 1, since Oct 17, 20234 company-led studies, 3 open or runningNext primary completion: Jun 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Base Therapeutics (Shanghai)43 open or runningearly phase 1since Oct 17, 2023Oct 17, 2023Jun 2027early phase 1 · NCT07166263

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2023First studies: 2 early phase 1 studiesFirst studyNCT06098898, NCT06117878
  2. Jul 16, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT07083349 · 4 enrolled · China
  3. Sep 3, 2025Early phase 1 study in Stomach NeoplasmsNCT07166263 · 15 planned · China

Ahead

  1. Jun 2027Primary completion: early phase 1 study in Stomach NeoplasmsNCT07166263

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07166263Stomach Neoplasms · ChinaEarly 1RecruitingJun 202715
NCT07083349Lupus Erythematosus, Systemic · ChinaEarly 1TerminatedApr 1, 20264
NCT06117878Osteosarcoma · ChinaEarly 1RecruitingSep 1, 202412
NCT06098898Stomach Neoplasms · ChinaEarly 1By invitationNov 1, 20249

How it is read

Names in the registry

  • “NK510”, 5 entries
  • “NK510 : allogeneic genetic modified NK”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.